Post by Vincenzo Quagliariello

📌 I'm thrilled to share our latest work just accepted on Cardio-Oncology journal titled " SGLT2i Dapagliflozin in primary prevention of chemotherapy-induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial" As co‑first author, I’m honored to contribute to this important multicentric study recently accepted and published in Cardio‑Oncology, part of the Springer Nature group ! The #PROTECT trial is the first randomized clinical study designed to evaluate whether #Dapagliflozin can reduce anthracycline- and/or trastuzumab-associated cardiotoxicity in patients with early-stage #breast #cancer. Beyond its established #cardiometabolic effects, this trial will also provide insight into the systemic anti-inflammatory and metabolic benefits of #SGLT2 inhibition in the #oncology setting. Findings from this study may pave the way for novel cardio-oncology strategies aimed at improving both cardiac outcomes and quality of life in cancer patients. Key highlights: 🎯 Study Design: A multicenter, randomized clinical trial exploring Dapagliflozin as a preventive strategy against cardiotoxicity during chemotherapy for early-stage breast cancer. 🎯Clinical Impact: If successful, the PROTECT trial may shift paradigms in cardio-oncology by incorporating SGLT2i into primary preventive care, offering a new layer of cardiac safety for patients undergoing potentially cardiotoxic cancer therapies. I’m genuinely excited about the translational potential of this work and grateful for the collaborative efforts that made it possible. Looking forward to seeing how the #PROTECT trial may pave the way for integrating cardioprotective therapies in oncology practice. 🏅 Thank you to all co-authors, collaborators, and the Springer Nature team for bringing this project to fruition. Alessandra Greco nicola maurea Gianpiero Rizzo @scelsi laura Andrea Tedeschi Maria Laura Canale and others IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy Stay tuned future results from PROTECT could meaningfully impact both cancer survivorship and cardiovascular care. https://lnkd.in/deYgF75v